|
|
Volumn 14, Issue 3, 2008, Pages 318-321
|
|
Perspectives on the "generic cliff" - Pushing and falling
a
a
CEBS
(United States)
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AMLODIPINE BESYLATE;
AMLODIPINE PLUS BENAZEPRIL;
ANTIDEPRESSANT AGENT;
ANTIHYPERTENSIVE AGENT;
ARIPIPRAZOLE;
ATORVASTATIN;
CALCIUM CHANNEL BLOCKING AGENT;
CETIRIZINE;
CITALOPRAM;
CLOPIDOGREL;
DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;
DOCETAXEL;
ENOXAPARIN;
ESOMEPRAZOLE;
FEXOFENADINE;
FLUINDOSTATIN;
FLUOXETINE;
GASTROINTESTINAL AGENT;
GENERIC DRUG;
IRBESARTAN;
NONSTEROID ANTIINFLAMMATORY AGENT;
PANTOPRAZOLE;
PIPERACILLIN PLUS TAZOBACTAM;
SIMVASTATIN;
TOPIRAMATE;
VENLAFAXINE;
ZOLPIDEM TARTRATE;
COST BENEFIT ANALYSIS;
COST CONTROL;
DRUG COST;
DRUG INDUSTRY;
DRUG MANUFACTURE;
DRUG PROGRAM;
DRUG RESEARCH;
DRUG UTILIZATION;
EDITORIAL;
HEALTH CARE COST;
HEALTH CARE PLANNING;
HEALTH INSURANCE;
HEARTBURN;
MANAGED CARE ORGANIZATION;
PATENT;
PHARMACY;
PRESCRIPTION;
PROSPECTIVE PAYMENT;
REIMBURSEMENT;
|
|
EID: 44049104760
PISSN: 10834087
EISSN: None
Source Type: Journal
DOI: 10.18553/jmcp.2008.14.3.318 Document Type: Editorial |
|
Times cited : (1)
|
|
References (21)
|
